|Bid||166.00 x 800|
|Ask||184.90 x 800|
|Day's Range||173.60 - 177.52|
|52 Week Range||79.88 - 178.16|
|Beta (3Y Monthly)||3.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||201.33|
On the same day as it cut the ribbon on its new Triangle patient support center, a Cambridge pharmaceutical company overcame the last regulation hurdle to bring its first-in-kind treatment to postpartum depression patients.
Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Drug Enforcement Administration (DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of the Controlled Substances Act. ZULRESSO, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, is the first and only treatment specifically approved for postpartum depression (PPD), the most common medical complication of childbirth. With this decision, the product label for ZULRESSO will be finalized.
SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for SAGE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SAGE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $1.84 billion over the last one-month into ETFs that hold SAGE are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,200 shares of its common stock, and 700 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 8:00 a.m.
President & CEO of Sage Therapeutics Inc (NASDAQ:SAGE) Jeffrey M Jonas sold 85,736 shares of SAGE on 05/29/2019 at an average price of $174.78 a share.
LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare ...
How far off is Sage Therapeutics, Inc. (NASDAQ:SAGE) from its intrinsic value? Using the most recent financial data...
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019 at 3:35 p.m.
The final winners are selected by the NEVYs Technology, Healthcare and Life Sciences Academies among a pool of nominees revealed in March. This year's seventh annual NEVYs marked the first time the Healthcare category had a dedicated Academy distinct from Life Sciences.
Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 8:40 a.m.
Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2019. “We started 2019 with positive data from a Phase 3 clinical trial of our lead oral compound SAGE-217 in postpartum depression and this was quickly followed by the FDA approval of ZULRESSO in PPD,” said Jeff Jonas, M.D., chief executive officer at Sage.
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:00 AM Eastern ...
NEW YORK, April 29, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Sage Therapeutics, Inc. (NASDAQGM: SAGE) concerning possible breaches of.
In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 A.M. ET to report its first quarter 2019 financial results and to discuss recent business updates. The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.
According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.